Corporate
Profile

Failed to register as Favorite Page
Failed to cancel as Favorite Page
This page is already registered as a Favorite Page
You can't add your company to your favorites.

Latest update： 17/12/2018 16:35:01
法人番号：9410001005130

ダイキョー精機株式会社

Inquiry

Overview

Corporate name ダイキョー精機株式会社
Corporate website http://www.daikyo-seiki.co.jp/
Head office: Country 日本
Head office: Address 〒018-0311 秋田県にかほ市金浦字蒲萄森41-1
Industry 精密機械・医療機械器具製造業
Inquiry

Similar Companies

Technos Co., Ltd.
We are a manufacturer specializing in automatic visual inspection systems. Our systems process images of products moving along the production line in plants for defect judgment, rather than relying on the human eye. This realizes far superior performance than human-eye inspection with our custom-developed electronic camera that has over 4000 times higher resolution than full hi-vision and a supercomputer that performs neural computing. The technology is patented in 14 countries worldwide. We have many dealings with leading manufacturers in 32 industries, including automobiles, steel, film, semiconductors, liquid crystal displays, and so on. We have done business with overseas companies as well.
K.K.SUNTECHNO
We started out as a manufacturer of ultra-small-diameter shafts and pins used for automobile parts and other purposes. Only a few manufacturers in Japan are dedicated to manufacturing ultra-small-diameter shafts. Our small-diameter shafts and pins are widely used in Japan and abroad. In 1997 we acquired licenses for manufacturing medical equipment and for manufacturing and selling medical equipment, and we began to manufacture and sell medical equipment for dental care. We are also tackling the development of medical equipment under industry-university-government collaboration. We directly export products overseas and import materials ourselves. We also manufacture pins for supercomputer recording media.
atDose Co., Ltd.
We have newly developed a mobile-type dosing and infusion device “atDose” (patent pending). With this device, we aim to create a medication platform that will fundamentally change the conventional treatment of serious diseases such as cancer.